Trial Profile
Treatment of poorly differentiated thyroid carcinoma resistant to conventional therapy, with reverse transcriptase inhibitors.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 29 Jul 2011 New trial record